Age- and sex-standardised rates of major adverse cardiovascular events (MACE) and cardiovascular (CV) death per 1000 person-years’ drug exposure and ORs of MACE and CV death as compared with imatinib use
| Imatinib | Dasatinib | Nilotinib | |
| Age- and sex-standardised MACE rate per 1000 person-years’ exposure (95% CI) | 14.2 (11.4 to 17.1) | 14.6 (7.3 to 22.0) | 31.2 (17.1 to 45.3) |
| Adjusted ORs (95% CI) for MACE | 1 | 0.67 (0.41 to 1.10) | 1.22 (0.70 to 1.97) |
| Age- and sex-standardised CV death rate per 1000 person-years’ exposure (95% CI) | 8.0 (5.9 to 10.1) | 15.2 (6.8 to 23.6) | 16.0 (5.7 to 24.5) |
| Adjusted ORs (95% CI) for CV death | 1 | 0.70 (0.42 to 1.17) | 0.89 (0.50 to 1.60) |
ORs are adjusted for a history of myocardial infarction, cerebrovascular disease, peripheral arterial disease, heart failure, diabetes, hypertension, chronic obstructive pulmonary disease and duration of exposure to each tyrosine kinase inhibitor.